1. Volume 15, Issue 4, Pages 457-463 (April 2014)
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial 
Prof Peter J Hoskin, FRCR, Amy A Kirkwood, MSc, Bilyana Popova, MSc, Paul Smith, MSc, Martin Robinson, FRCR, Eve Gallop-Evans, FRCR, Stewart Coltart, FRCR, Prof Timothy Illidge, FRCR, Krishnaswamy Madhavan, FRCR, Caroline Brammer, FRCR, Patricia Diez, MSc, Prof Andrew Jack, FRCPath, Isabel Syndikus, FRCR 
The Lancet Oncology 
Volume 15, Issue 4, Pages (April 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
All numbers refer to randomised sites, not patients. *All radiotherapy target sites are included in the analysis of local progression (the primary endpoint).
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Progression-free survival for all sites (A) and overall survival for one site per patient (B)
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions